Eli Lilly - Public Comps and Valuation Multiples

Eli Lilly Overview

About Eli Lilly

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Founded

1901

HQ

Employees

47K+

Website

lilly.com

Sectors

Biopharmaceuticals
Drug Development & Therapeutics
BioTech

Financials

Last FY Revenue $45.0B

Last FY EBITDA $15.2B

EV

$1000B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Eli Lilly Financials

See Eli Lilly valuation multiples based on analyst estimates

Eli Lilly P&L

In the most recent fiscal year, Eli Lilly reported revenue of $45.0B and EBITDA of $15.2B.

Eli Lilly expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Eli Lilly valuation multiples based on analyst estimates

	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue	XXX	$45.0B	XXX	XXX	XXX
Gross Profit	XXX	$36.6B	XXX	XXX	XXX
Gross Margin	XXX	81%	XXX	XXX	XXX
EBITDA	XXX	$15.2B	XXX	XXX	XXX
EBITDA Margin	XXX	34%	XXX	XXX	XXX
EBIT	XXX	$17.5B	XXX	XXX	XXX
EBIT Margin	XXX	39%	XXX	XXX	XXX
Net Profit	XXX	$10.6B	XXX	XXX	XXX
Net Margin	XXX	24%	XXX	XXX	XXX
Net Debt	XXX	$30.4B	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Eli Lilly including revenue, profitability, and margin analysis across different time periods. In the most recent fiscal year, Eli Lilly achieved $45.0B in revenue and $15.2B in EBITDA.
Financial Metric	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2026)	Next Fiscal Year (2027)	Two Years Forward (2028)
Total Revenue	Analyst estimates available to subscribers	$45.0B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	Analyst estimates available to subscribers	$36.6B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	Analyst estimates available to subscribers	81.3% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	Analyst estimates available to subscribers	$15.2B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	Analyst estimates available to subscribers	33.8% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	Analyst estimates available to subscribers	$17.5B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	Analyst estimates available to subscribers	38.9% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	Analyst estimates available to subscribers	$10.6B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	Analyst estimates available to subscribers	23.5% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	$30.4B	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Eli Lilly

This financial data table provides comprehensive performance metrics for Eli Lilly, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Fiscal Year Performance

In the most recent fiscal year, Eli Lilly reported $45.0B in total revenue.
Fiscal year EBITDA was $15.2B.
The company maintained a gross profit margin of 81.3% in the most recent fiscal year.
EBITDA margin for the fiscal year was 33.8%.
Net profit margin reached 23.5% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Eli Lilly. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Eli Lilly Stock Performance

Eli Lilly has current market cap of $967B, and EV of $1000B.

Market Cap Evolution

Eli Lilly Stock Data

As of January 5, 2026, Eli Lilly's stock price is $1080.

See Eli Lilly trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$1000B	$967B	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Eli Lilly Valuation Multiples

Eli Lilly's trades at 22.2x EV/Revenue multiple, and 65.6x EV/EBITDA.

See valuation multiples for Eli Lilly and 15K+ public comps

Eli Lilly Financial Valuation Multiples

As of January 5, 2026, Eli Lilly has market cap of $967B and EV of $1000B.

Equity research analysts estimate Eli Lilly's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Eli Lilly's P/E ratio is not available.

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Market cap (current)	$967B	XXX	$967B	XXX	XXX	XXX
EV (current)	$1000B	XXX	$1000B	XXX	XXX	XXX
EV/Revenue	n/a	XXX	22.2x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	65.6x	XXX	XXX	XXX
EV/EBIT	n/a	XXX	57.1x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	n/a	XXX	91.3x	XXX	XXX	XXX
EV/FCF	n/a	XXX	2412.6x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Eli Lilly Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Eli Lilly Margins & Growth Rates

Eli Lilly's revenue per employee in the last FY averaged $1.0M, while opex per employee averaged $0.4M for the same period.

Eli Lilly's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Eli Lilly's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Eli Lilly and other 15K+ public comps

Eli Lilly Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	34%	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$1.0M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.4M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	24%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	42%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial